arrow
C

Claudia D. Baldus

University Hospital Schleswig-Holstein
H指数:56
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist

一种涵盖无细胞系的亚组、可连续移植的急性髓系白血病PDX模型平台

2026-10-050
OAAI
Alterations in 3D-DNA architecture drive unique leukemic profiles in IDH1- and DNMT3A-mutant acute myeloid leukemia

IDH1和DNMT3A突变急性髓系白血病中3D-DNA结构的改变驱动独特的白血病表型

Leukemia
IF13.4
2026-10-010
OAAI
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study

吉列替尼与异基因造血干细胞移植序贯治疗复发/难治FMS样酪氨酸激酶3(FLT3)突变急性髓系白血病患者的多中心真实世界研究

2026-09-050
OAAI
Functional characterization of snoRNA-derived RNA (sdRNA) expression in healthy hematopoiesis and acute myeloid leukemia

在健康造血和急性髓系白血病中snoRNA衍生RNA(sdRNA)表达的分子功能鉴定

Leukemia
IF13.4
2026-09-040
OA
Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
Leukemia
IF13.4
2026-08-310
OA
IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL

IntegrateALL:一种用于多层级数据提取和可解释亚型分类的B-前体ALL端到端RNA-seq分析流程

2026-04-160
OAAI
Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemia

异柠檬酸脱氢酶1突变驱动白细胞介素1受体1的下调及急性髓系白血病中失调的炎症反应

2026-01-060
OAAI
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy
2026-01-010
OAAI
RoCK and ROI: single-cell transcriptomics with multiplexed enrichment of selected transcripts and region-specific sequencing

RoCK 和 ROI:通过选择转录本的多次富集和区域特异性测序的单细胞转录组学

2025-12-100
OA
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

阿扎胞苷治疗具有可测量残留病灶的患者中的骨髓增生异常综合征/急性髓系白血病:RELAZA2试验的最终长期结果

Blood
IF23.1
2025-12-100
PRE
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial

非侵入性基因分型及早期疾病动态变化表明,在TRIANGLE试验中接受治疗的套细胞淋巴瘤患者中,伊布替尼联合免疫化疗的疗效。

Leukemia
IF13.4
2025-11-030
OAAI
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study

ctDNA动力学证明了tafasitamab + R-CHOP +/- lenalidomide的快速治疗反应,并能预测弥漫性大B细胞淋巴瘤的结局:First-MIND 1b期研究结果

Leukemia
IF13.4
2025-10-270
OA
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients

4978例接受强化治疗的AML欧洲患者队列中,髓系发育异常相关基因突变的不同预后影响

Leukemia
IF13.4
2025-10-270
OA
Epidemiology, survival, and treatment of acute myeloid and lymphoblastic leukaemia in Germany: a nationwide population-based registry analysis

流行病学、生存率及急性髓系和淋巴母细胞白血病的治疗:德国一项基于全国人口登记库的分析

2025-10-180
OAAI
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial

低甲基化治疗联合或不联合艾曲波帕治疗老年急性髓系白血病患者:来自随机、安慰剂对照的II期DELTA试验结果

2025-10-020
OAAI
Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells

通过干扰tRNA修饰靶向药物抵抗性白血病细胞中的线粒体易损性

Blood
IF23.1
2025-08-050
OAAI
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis

吉姆单抗奥佐米星在CBF-AML一线治疗中的应用:一项回顾性多中心分析的见解

Leukemia
IF13.4
2025-07-210
OA
Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment

CPX-351在急性髓系白血病中的诱导化疗:重新评估早期骨髓评估的作用

Leukemia
IF13.4
2025-07-030
OAAI
NGS-based IG/TR gene rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation

基于NGS的IG/TR基因重排分析在急性淋巴细胞白血病中的应用:免疫遗传学成熟的年龄依赖性

Blood
IF23.1
2025-03-270
PREAI